Optimize Antigen-Specific Immune Tolerance Induction Strategies, Accelerate Safe and Effective Translation into the Clinic & Expand Opportunities Through Combination Therapies

Expert Speakers Including:

Amy Rosenberg  
Supervisory Medical Officer and Division Director, Office of Biotechnology Products CDER/FDA

Carla Greenbaum  
Director - Diabetes Program Benaroya Research Institute

Gerald (Jerry) Nepom  
Director Immune Tolerance Network

Anne De Groot  
CEO & CSO EpiVax

Matthias von Herrath  
Professor at the La Jolla Institute for Allergy & Immunology; VP of T1D R&D Center Seattle Novo Nordisk

Robert (Bob) Anderson  
CSO ImmusanT

Jack Ragheb  
Senior Medical Fellow for Immunology - Global Patient Safety Eli Lilly

Michael Boyne  
VP of Product Development & Analytics Cour Pharmaceuticals

Kei Kishimoto  
CSO Selecta Biosciences

Proud To Partner With:

ANOKION  Topas Therapeutics  ORION Bioscience Inc.  NEKTAR  SELECTA Biosciences
Why our speakers are looking forward to this summit?

"I look forward to presenting our new, unpublished research on Tregitopes to a gathering of my peers."
- Anne De Groot, CEO & CSO, EpiVax

"Pulling together speakers from across the field of antigen-specific tolerance translation into a single focused meeting is what excites me about this summit."
- Ranjeny Thomas, Professor of Rheumatology at University of Queensland; Director, Dendright

Why Attend the 2nd Antigen-Specific Immune Tolerance Drug Development Summit 2019?

1. Benchmark against the latest understandings of antigen-specific immune tolerance strategies as therapeutic targets in allergy and autoimmune diseases with insights from Immune Tolerance Network, Eli Lilly & Dendright.

2. Widen your expertise on identification & validation of novel targets & mechanism of actions for effective antigen-specific immune tolerance induction with insights from GSK, EpiVax & University of Zurich.

3. Overcome key design and optimization challenges of antigen-specific delivery systems with insights from Topas Therapeutics, SQZ Biotechnologies & Northwestern University.

4. Increase your translational success rate with case studies on how to overcome challenges of animal model studies and identification/validation of human biomarkers from Novo Nordisk, ImmusanT & Akston Biosciences.

5. Optimize your clinical trial strategy by hearing the latest insights from patient data of the most advanced antigen-specific immune tolerance clinical programs from Selecta Biosciences, Cour Pharmaceuticals & ImmusanT.

6. Join the momentum to re-define the antigen-specific immune tolerance induction strategies & widen the opportunities through combination therapies with insights from FDA, Prevention Bio & ActoBio Therapeutics.
YOUR EXPERT SPEAKERS

Carla Greenbaum  
Director- Diabetes Program  
Benaroya Research Institute

Gerald (Jerry) Nepom  
Director  
Immune Tolerance Network

David Wraith  
Institute Director of Immunology & Immunotherapy and Professor of Immunology  
University of Birmingham

Amy Rosenberg  
Supervisory Medical Officer and Division Director, Office of Biotechnology Products  
CDER/FDA

Ranjeny Thomas  
Professor of Rheumatology at University of Queensland; Director  
Dendright

Erika von Mutius  
Professor of Pediatric Allergology  
Dr. von Hauner Children’s Hospital

Jack Ragheb  
Senior Medical Fellow for Immunology- Global Patient Safety  
Eli Lilly

Robert (Bob) Anderson  
CSO  
ImmuSanT

Michael Boyne  
VP of Product Development & Analytics  
Cour Pharmaceuticals

Stephan Kontos  
Co-founder & CSO  
Anokion

Anne De Groot  
CEO & CSO  
EpiVax

Lotta Jansson  
Chief Research Officer  
Apitope

Timm Jessen  
CEO  
Topas Therapeutics

Roland Martin  
Head- Department of Neuroimmunology & Multiple Sclerosis Research  
Neurology Clinic  
University Hospital Zurich, University of Zurich

Charlotte Fribert  
CEO  
ToleranZi AB

Kei Kishimoto  
CSO  
Selecta Biosciences

Stephen Miller  
Co-founder of Cour Pharmaceuticals; Professor of Microbiology-Immunology  
Northwestern University Medical School

Francisco Leon  
CSO  
Provention Bio

Pieter Rottiers  
CEO  
ActoBio Therapeutics

Finola Moore  
Associate Director of Immune Tolerance  
SQZ Biotechnologies

Matthias von Herrath  
Professor at the La Jolla Institute for Allergy & Immunology; VP of TID R&D Center Seattle  
Novo Nordisk

David Alleva  
Executive Director- Immunotherapeutics  
Akston Biosciences

Joshua Sestak  
President & CSO  
Orion BioScience

Simi Ahmed  
Director, Research  
JDRF

Yoav Messinger  
Medical Director- Cancer and Blood Disorders  
Children’s Hospitals and Clinics of Minnesota

Xunrong Luo  
Director-Translational Research  
Duke Transplant Center, Duke University

Andreas Lutterotti  
MD; Assistant Professor- Experimental Therapy Research in Multiple Sclerosis  
University of Zurich
WHY ARE OUR EXPERT SPEAKERS GETTING INVOLVED AT THE SUMMIT?

“I look forward to further exchanges with specialists in the field of Antigen-Specific Immune Tolerance, to deepen and broaden dialog started at the first Antigen-Specific Immune Tolerance Summit in Boston, which was quite illuminating.”

Charlotte Friibert
CEO
Toleranz AB

“This meeting will provide opportunities to network with key scientists, hear about the latest developments and state-of-the-art science in the field of immune tolerance.”

Antoon Van Oosterhout
VP & Head Allergic Inflammation Discovery Performance Unit
GSK

“This meeting is an ideal opportunity to gain insight into new tolerance strategies and obtain an overview of the existing field.”

Jack Ragheb
Senior Medical Fellow for Immunology- Global Patient Safety
Eli Lilly

“I look forward to participating at this summit as cross-disease and cross-discipline exchanges are critical if we are to make disease-modifying therapy a reality in type 1 diabetes.”

Carla Greenbaum
Director- Diabetes Program
Benaroya Research Institute

“I look forward to exchanging ideas and concepts on immune tolerance across the different perspectives from academia, biotech and pharma.”

Andreas Lutterotti
MD; Assistant Professor- Experimental Therapy Research in Multiple Sclerosis
University of Zurich

“The meeting is an excellent event for networking but also an opinion generator/former for developing these novel therapeutics clinically in the exciting field of antigen-specific immune tolerance induction.”

Timm Jessen
CEO
Topas Therapeutics
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.00</td>
<td><strong>Registration &amp; Networking Breakfast</strong></td>
</tr>
<tr>
<td>8.50</td>
<td><strong>Chair's Opening Remarks</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Carla Greenbaum</strong>&lt;br&gt;Director- Diabetes Program&lt;br&gt;Benaroya Research Institute</td>
</tr>
<tr>
<td>9.00</td>
<td><strong>Antigen-Specific T Cell Profiles as Therapeutic Targets in Allergy and Autoimmune Disease</strong>&lt;br&gt;• High-dimensional phenotyping identifies distinct antigen-specific T cell profiles using peripheral blood from patients with allergy and autoimmune disease&lt;br&gt;• Deletion, deviation, anergy, and exhaustion are potential tolerogenic outcomes of therapy&lt;br&gt;• Tracking antigen-specific T cells during therapy may be a surrogate for clinical response</td>
</tr>
<tr>
<td>9.30</td>
<td><strong>Antigen-Specific Immunotherapy for Treatment of Autoimmune Diseases</strong>&lt;br&gt;• A review of different approaches for induction of antigen-specific immunotherapy&lt;br&gt;• A report on recent clinical trials of the approach for immunotherapy of autoimmune diseases&lt;br&gt;• A discussion on the potential for combination approaches to promote antigen-specific immunotherapy</td>
</tr>
<tr>
<td>10.00</td>
<td><strong>Antigen Specific Approaches to Food Allergy &amp; Immunogenicity</strong>&lt;br&gt;• Inducing tolerance without immune suppression by harnessing nanoparticle technology&lt;br&gt;• Proof of principle data for Peanut Allergy&lt;br&gt;• Proof of principle data for Recombinant Proteins</td>
</tr>
<tr>
<td>10.30</td>
<td><strong>Speed Networking &amp; Morning Refreshments</strong></td>
</tr>
<tr>
<td>11.30</td>
<td><strong>Protection from Childhood Allergies &amp; Inflammatory Bowel Disease</strong>&lt;br&gt;• Prevention of allergic and autoimmune diseases in environment rich microbial exposure&lt;br&gt;• Potential mechanisms of preventive approach&lt;br&gt;• Translational aspects and considerations</td>
</tr>
<tr>
<td>12.00</td>
<td><strong>Anti-Drug Antibody Responses: Past, Present &amp; Future</strong>&lt;br&gt;• Review the history of ADA responses&lt;br&gt;• Review the present state of ADA responses&lt;br&gt;• Discuss the future state of ADA responses</td>
</tr>
</tbody>
</table>
12.30 Antigen-Specific Tolerance for Transplantation
- A top-down approach can be used to overcome the complexity of alloantigens for transplantation tolerance
- Multiple parallel mechanisms involving both innate and adaptive immune cells are implicated for transplantation tolerance
- B cells play a critical role in tolerance resistance in pre-sensitized hosts

13.00 Networking Lunch

Identification & Validation of Novel Targets & Mechanism of Actions for Antigen-Specific Immune Tolerance Induction

14.00 Targeted Antigen Delivery to the Liver via Synthetic Glycosylation Induces Robust Antigen-Specific Tolerance
- Active targeting domains deliver antigen to tolerogenic pathways in the liver, and induce robust antigen-specific tolerance in both mouse and non-human primate models of immunity
- Our technologies are translational, in that the mechanisms induced are consistent with unmet clinical needs, and our molecules are developable
- Discuss potential approaches to de-risk MoA’s in higher-order species, and consider their value

14.30 Antigen-Specific Tolerance Induction in Rheumatoid Arthritis
- What are the opportunities and challenges of antigen-specific tolerance induction in a systemic inflammatory autoimmune disease?
- How does the autoimmune induction phase differ from the inflammatory effector phase in rheumatoid arthritis and what are the implications for therapeutic tolerising strategies?
- What type of immunomonitoring could contribute to evaluation of the outcome of tolerising strategies in rheumatoid arthritis?

15.00 Target Identification in Immune-Mediated Disorders Including Autoimmune Diseases, Allergies, Anti-Drug Responses & Tumor Immunology
- Unbiased and systematic identification of target antigens for T cells using combinatorial chemistry and bioinformatics
- Identification of disease-relevant T cells in autoimmune diseases
- How does the autoimmune T cell response relate to recognition of foreign antigens as triggers?

15.30 Afternoon Refreshments & Poster Session

Advancing Pre-Clinical Development of Novel Antigen-Specific Immune Tolerance Therapies

16.00 TOL2: An Antigen Specific Tolerogenic Therapy for the Treatment of Myasthenia Gravis
- TOL2 treatment modalities
- Tolerance induction and maintenance using TOL2
- Preclinical development of TOL2
16.30 **Engineering Red Blood Cells for Immune Tolerance Using Cell Squeeze® Technology**
- The SQZ process efficiently delivers antigen into red blood cells (RBCs) and primes cells for rapid clearance in the liver and spleen
- SQZ’d RBCs reduce CD4+ and CD8+ T cell responses against model antigens and human autoantigens
- SQZ’d RBCs delay or prevent onset of T1D in adoptive transfer model

17.00 **Panel Discussion: How to Identify & Prioritize the Route to Success for Antigen-Specific Immune Tolerance Induction Strategies?**
- What does it take to achieve a robust proof-of-concept for antigen-specific immune tolerance induction strategies in complex auto-immune mediated diseases?
- Delivering on the hype and investment thus far – how to translate promising science and clear opportunity into safe and effective antigen-specific tolerance inducing therapeutics?
- The most promising route to funding: how to secure funding, through cross-industry collaborations, to fuel early clinical trial studies and beyond?

Moderator: Charlotte Fribert
CEO
Toleranzi AB

Panelists:
- **Matthias von Herrath**
Professor at the La Jolla Institute for Allergy & Immunology; VP of T1D R&D Center Seattle
Novo Nordisk
- **David Alleva**
Executive Director-Immuno-therapeutics
Akston Biosciences
- **Joshua Sestak**
President & CSO
Orion BioScience
- **Lotta Jansson**
Chief Research Officer
Apitope

17.30 **Chair’s Closing Remarks & End of Day One**

“Progress in immune tolerance therapies transcends individual diseases or single therapeutic platforms. We can share ideas and learn from eachother in order to move forward with optimized clinical strategies and trials”

Gerald (Jerry) Nepom, Director, Immune Tolerance Network
Optimization of Tolerance Delivery Systems & Translation of Antigen-Specific Tolerance Strategies into Clinic

**8.30 Mechanisms Underlying Tolerance Induction with Antigen-Encapsulating PLG Nanoparticles**
- Tolerance induction using antigen-encapsulating PLG nanoparticles (Ag-PLG) recapitulates how self-tolerance is maintained in the hematopoietic system
- Ag-PLG uptake by splenic and liver APCs confers a tolerogenic phenotype
- Ag-PLG induces the induction of CD4+Foxp3+ and CD8+CD122+ regulatory T cells

**9.00 Antigen-Specific Targeting of B Cells in Type 1 Diabetes**
- Insulin-specific B cells promote T1D pathogenesis by acting as antigen-presenting cells (APCs) that activate pathogenic effector T cells
- Antigen-specific deletion of such B cells has not yet been successful, mainly because of the requirement of a fully-conformational antigen that contains a deletional mechanism. Akston has created such a therapeutic, AKS-107
- The presence of autoantibodies produced by autoreactive B cells allows for feasible clinical biomarker assays for both entry criteria (patient stratification) and therapeutic response monitoring

**9.30 Soluble Antigen Arrays’ Mimic Peripheral Tolerance to Intercept Autoimmune Disease and Restore Health**
- The importance of restoring tolerance mechanisms after an autoimmune break
- The role of physiochemical as well as molecular properties in therapeutic design
- The value of leveraging safety in early stage or adolescent autoimmune disease patients

**10.00 Morning Refreshments & Networking**

**10.30 Preparation of Liver-Targeting Nanoparticles for Clinical Trials**
- The liver as tolerance mediator
- Nanoparticles as therapeutic agents
- Regulatory aspects of nanomedicine

**11.00 Obstacles for Bringing Antigenic Tolerance Induction to the Clinic**
- Front runners can be chosen with smart in vivo and in vitro comparative assays
- A key obstacle for clinical development of antigenic tolerance induction is the lack of human biomarkers as surrogate endpoint in safety/dosing trials
- We do not understand how tolerance is optimally achieved in humans (regulation versus exhaustion versus anergy versus deletion)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presentation</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>Networking Lunch</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 12.30 | Fulfilling the Future of Tolerance Clinical Development with Insights from Patient Data | **12.30 Preclinical & Clinical Development of Tolerogenic Nanoparticles to Mitigate Immunogenicity of Biotherapeutics**  
   - Immunogenicity is a major cause of treatment failure for many biologic therapies  
   - Selecta Biosciences has developed rapamycin-carrying nanoparticles to mitigate immunogenicity to a wide variety of biologics  
   - An update on preclinical applications, including gene therapy, and early clinical data from a Phase 2 trial with an enzyme therapy for the treatment of severe gout | Kei Kishimoto  
CSO  
Selecta Biosciences |
| 13.00 | Immunotherapy for Celiac Disease Using Immuno-Dominant Gluten Epitopes (Nexvax2®) – Discovery to Phase 2 | **13.00 Immunotherapy for Celiac Disease Using Immuno-Dominant Gluten Epitopes (Nexvax2®) – Discovery to Phase 2**  
   - Celiac disease, as both a food hypersensitivity and autoimmune disease, facilitates antigen challenge in patients that is enabling for epitope identification, biomarker discovery, and efficacy assessment  
   - The first dose effect observed when immuno-dominant gluten epitopes are administered systemically recapitulates cytokine release and symptoms caused by gluten ingestion in celiac disease  
   - Stepwise up dosing allows immuno-dominant gluten epitopes to be administered in a standardized regimen that uniformly achieves immune non-responsiveness to dose levels that are well above the MTD for single dose exposure | Robert (Bob) Anderson  
CSO  
ImmusanT |
| 13.30 | Lessons Learned from Multi-Center Trials of Antigen Therapy in T1D             | **13.30 Lessons Learned from Multi-Center Trials of Antigen Therapy in T1D**  
   - What are the specific clinical trial design considerations for multi-center trials of antigen therapy in T1D?  
   - How to get around the practical problems of running a multi-center GCP clinical trial?  
   - TrialNet observations as a solution led case study | Carla Greenbaum  
Director- Diabetes Program  
Benaroya Research Institute |
| 14.00 | Long-Term Consequences of Tolerance Induction Strategies Using Anti-B-Cell (Rituximab), Especially to the Growing Child: Lessons Learned from Oncology & Pompe Disease | **14.00 Long-Term Consequences of Tolerance Induction Strategies Using Anti-B-Cell (Rituximab), Especially to the Growing Child: Lessons Learned from Oncology & Pompe Disease**  
   - If immune modulation includes anti-B-cell agents, a proportion of patients exposed to Rituximab develop long-term B-cell dysfunction  
   - Successful tolerance induction to enzyme replacement (ERT) for infantile Pompe disease includes rituximab. However, some patients are left with ongoing IVIG requirement and long-term B-cell dysfunction  
   - Monitoring guidelines are suggested | Yoav Messinger  
Medical Director- Cancer and Blood Disorders  
Children’s Hospitals and Clinics of Minnesota |
| 14.30 | Afternoon Refreshments & Networking                                           |                                                                                                         |         |
| 15.00 | The Future Landscape of Antigen-Specific Immune Tolerance Therapies: The Promise of Combination Strategies | **15.00 Combining Induction with Consolidation Therapy in ITN Clinical Trials for Autoimmunity**  
   - Induction therapy targets persistent effector cells that are a barrier to durable response  
   - Consolidation therapy allows homeostatic and regulatory mechanisms to mature  
   - Sequential combinations of induction and consolidation offer prospects for tolerogenic outcomes | Gerald (Jerry) Nepom  
Director  
Immune Tolerance Network |
### 15.30 Tregitopes Induce Active Tolerance in Autoimmune Diabetes & Allergy

Anne De Groot  
CEO & CSO  
EpiVax

- Tregitopes (natural T cell epitopes derived from IgG) that (a) bind to multiple MHC class II molecules, (b) suppress effector T cell responses to co-delivered antigen, and (c) up-regulate Treg-associated cytokines and chemokines  
- Tregitopes promote tolerance by activating Regulatory T cell (Treg) activity and expanding Tregs in vitro and in vivo  
- Tregitopes provide an explanation for the mechanism of action IVIg on DC and T-cells and may ultimately provide a safe alternative to plasma-based immune regulation therapies  
- Case study on combination of Tregitope-albumin fusions and PPI peptides (T1D ASATI): Antigen-specific adaptive tolerance induction (ASATI) is induced when antigens are administered in combination with Tregitopes

### 16.00 Immune Modulation + Antigen Specificity: Exploring Combination Approaches for Tolerance Induction & Maintenance in Autoimmunity & Immunogenicity

Francisco Leon  
CSO  
Provention Bio

- The combination of immune-modulatory agents and antigen-specific approaches may yield superior efficacy in the induction and maintenance of immune tolerance  
- A review of the unmet need in autoimmunity and in the immunogenicity of therapeutic agents, as well as current attempts to address the issue  
- The combination of a T cell modulator (teplizumab) and a B cell inhibitor (PRV-3279) with antigen-specific approaches will be presented as examples

### 16.30 Panel Discussion: Evaluation of Combination Therapies to Address Unmet Clinical Needs

- What are the translational challenges of combination therapies in the context of disease complexity and mechanism of action?  
- What are the regulatory guidelines and considerations for combining two unapproved drugs as a combination strategy?  
- What is the expected value-split between the stakeholders?

**Moderator:**  
Finola Moore  
Associate Director of Immune Tolerance  
SQZ Biotechnologies

**Panelists:**  
Amy Rosenberg  
Supervisory Medical Officer and Division Director, Office of Biotechnology Products  
CDER/FDA  
Pieter Rottiers  
CEO  
ActoBio Therapeutics

Lotta Jansson  
Chief Research Officer  
Apitope

### 17.00 Chair’s Closing Remarks & Close of 2nd Antigen-Specific Immune Tolerance Drug Development Summit 2019

Don’t miss out on the technical workshop day on next page!
The purpose of this workshop is to bring together experts across autoimmune fields to discuss common challenges facing clinical translation of antigen specific therapies. Topics of key relevance include defining a late stage preclinical development path of therapeutic candidates, common cross disease challenges in identifying reliable mechanistic markers of immune effects of antigen specific therapies, possible need for de-bulking therapies or other combinations to ensure success of these types of therapies, and how multiple stakeholders might come together in public-private partnership to overcome common hurdles.

Hear & Discuss About:
• Need for harmonized approaches in this space and novel ways to address them
• Blood mechanistic markers to evaluate treatment and therapeutic response of antigen specific therapies
• Improving the predictability and effective utilization of preclinical models as pre-requisites for clinical testing
• Lessons learnt from successful clinical testing of antigen specific therapies across diseases

Workshop B
11:30am – 14:00pm
Antigen-Specific Tolerance Induction: Robust Strategies to Improve Clinical Trials Efficacy & Success Rate

This interactive workshop session will delve deep into the challenges associated with the lack of robustness in terms of proof of concept in the field of antigen-specific immune tolerance induction, clinical efficacy in relation to mechanism of action and strategic considerations for developing clinical trial protocols to optimize successful translation into and through different phases of clinical trials.

Hear & Discuss About:
• How to document clinical efficacy in relation to mechanism of action?
• Outcome measure
• Clinical trial protocols and critical steps to consider (phase Ila as PoC component)
• Regulatory issues (advanced therapy medicinal products (ATMP) versus biological, nanoparticle)

Workshop Leader
Andreas Lutterotti
MD; Assistant Professor- Experimental Therapy Research in Multiple Sclerosis University of Zurich

Andreas Lutterotti is Assistant Professor for “Experimental Therapy Research in Multiple Sclerosis and Other Neurological Diseases” at the University of Zurich since August 2014. His core expertise is the development and implementation of experimental therapies in the field of multiple sclerosis and other autoimmune diseases. He is Co-Founder of Cellerys AG, a company developing a cell based therapy to induce immune tolerance in MS.
This informative workshop highlights potential regulatory and R&D strategies to combine antigen-specific immune tolerance approaches with other therapies in order to open up the potentials to address a wider unmet patient need across various therapeutic areas.

Hear & Discuss About:

- When might combination strategies be applicable to treatment of autoimmune disease?
- What types of combination strategies might be used in autoimmune disease and is there evidence from the clinic already?
- Does combination always mean simultaneous?
- How could immunomonitoring be applied to trials of combination tolerising therapies?
- Considerations for clinical trial design
- How does the regulatory landscape change if developing a combination therapy based on two unapproved drugs?

**Workshop Leaders**

**Amy Rosenberg**
Supervisory Medical Officer and Division Director, Office of Biotechnology Products
CDER/FDA

Amy Rosenberg received her MD from Albert Einstein College of Medicine and is Board Certified in Internal Medicine. She joined CBER, FDA in 1988, becoming Director of the Division of Therapeutic Proteins, CBER/CDER in 2000 (now DBRR3 in the Office of Biotechnology Products, CDER). She has been a driving force in risk evaluation and mitigation pertaining to the immunogenicity of therapeutic proteins and in the elucidation and implementation of immune tolerance induction protocols in clinical settings.

**Ranjeny Thomas**
Professor of Rheumatology at University of Queensland; Director
Dendright

Ranjeny Thomas is Professor of Rheumatology at University of Queensland as well as founder and a director of the spin-off company, Dendright, which is developing immunotherapy for autoimmune diseases. Her research seeks to understand autoimmune disease and restoration of immune tolerance. Through this work, she developed and tested the first rheumatoid arthritis vaccine.

“’The development of antigen-specific tolerization is currently taking important steps, but critical questions have remained open. I see this conference as an excellent venue to exchange ideas with other investigators in this field”’

Roland Martin, Head- Department of Neuroimmunology & Multiple Sclerosis Research, Neurology Clinic University Hospital Zurich, University of Zurich
Topas Therapeutics (Hamburg, Germany) is focused on developing products in areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. Topas’ technology induces antigen-specific regulatory T cells in the liver by mimicking bloodborne antigens via the Company’s proprietary peptide-loaded nanoparticles. Topas has programs in MS, T1D and an orphan indication, which is planned to enter the clinic in 2019. The Company has collaborations with Eli Lilly and Company and with Evotec.

www.topas-therapeutics.com

Orion BioScience Inc. is a preclinical stage biotechnology company focused on developing our “Soluble Antigen Array” (or SAgA) technology to intercept and prevent the onset of autoimmune diseases in at risk and early stage patients. Our research into treating multiple sclerosis, neuromyelitis optica, and type-1 diabetes has shown that Orion can develop disease specific immunotherapeutics that can re-tolerize and restore the healthy immune state. The Orion team leverages extensive development experience, and strong clinical relationships, to rapidly progress first-in-class, blockbuster treatments for NMO and T1D into the clinic.

www.orionbioscience.com

Anokion is a leading immune tolerance company advancing novel, antigen-specific treatments for people living with the devastating effects of autoimmune disease. Anokion is strategically progressing its development pipeline based on an industry-leading, novel platform that harnesses the body’s natural tolerance pathways. Initially formed as a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), the company is funded by leading investors, including Versant Ventures, Novo Ventures, and Novartis Venture Fund. For more information, please visit

www.anokion.com

Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform. Selecta plans to combine ImmTOR with a range of biologic therapies for rare and serious diseases that require new treatment options due to high immunogenicity. The company’s current proprietary pipeline includes ImmTOR-powered therapeutic enzyme and gene therapy product candidates.

www.selectabio.com

**Brand Partner**

**Topas Therapeutics**

**Brand Partner**

**Orion BioScience Inc.**

**Brand Partner**

**Nektar Therapeutics**

**Event Partner**

**Selecta Biosciences, Inc.**

**Innovation Partner**

**Anokion**

**Brand Partner**

**Orion BioScience Inc.**

**Brand Partner**

**Nektar Therapeutics**

**Event Partner**

**Selecta Biosciences, Inc.**

**GET INVOLVED**

Tel: +1 617 455 4188  Mail: info@hansonwade.com

www.as-immunetolerance.com
3 EASY WAYS TO BOOK

Web: www.as-immunetolerance.com
Tel: +1 617 455 4188
Email: register@hansonwade.com

Team Discounts*
• 10% discount – 3 delegates
• 15% discount – 4 delegates
• 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.
Contact: register@hansonwade.com

SECURE YOUR PLACE

<table>
<thead>
<tr>
<th>Industry Pricing</th>
<th>Standard Prices</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference + 3 Workshops</td>
<td>$4,099</td>
</tr>
<tr>
<td>Conference + 2 Workshops</td>
<td>$3,799</td>
</tr>
<tr>
<td>Conference + 1 Workshop</td>
<td>$3,399</td>
</tr>
<tr>
<td>Conference Only</td>
<td>$2,899</td>
</tr>
<tr>
<td>Workshops (Each)</td>
<td>$599</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Academic &amp; Not-for-Profit Pricing</th>
<th>Standard Prices</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference + 3 Workshops</td>
<td>$2,799</td>
</tr>
<tr>
<td>Conference + 2 Workshops</td>
<td>$2,599</td>
</tr>
<tr>
<td>Conference + 1 Workshop</td>
<td>$2,299</td>
</tr>
<tr>
<td>Conference Only</td>
<td>$1,899</td>
</tr>
<tr>
<td>Workshops (Each)</td>
<td>$499</td>
</tr>
</tbody>
</table>

1. Discuss and learn more about antigen-specific tolerance induction strategies with cross-disciplinary insights from the fields of transplantation, allergy and autoimmunity
2. Overcome challenges of delivery system optimization and robust translation into clinic through case studies focused on improvement of animal models, biomarker identification/validation studies and early clinical trial considerations
3. Define future scientific and strategic trends of the field with insights from clinical patient data to ensure successful antigen-specific immune tolerance drug development, both as a stand-alone approach or in combination with other strategies

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including, without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

TEAM DISCOUNTS
- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.
Contact: register@hansonwade.com

Industry Pricing
- Conference + 3 Workshops: $4,099
- Conference + 2 Workshops: $3,799
- Conference + 1 Workshop: $3,399
- Conference Only: $2,899
- Workshops (Each): $599

Academic & Not-for-Profit Pricing
- Conference + 3 Workshops: $2,799
- Conference + 2 Workshops: $2,599
- Conference + 1 Workshop: $2,299
- Conference Only: $1,899
- Workshops (Each): $499

Wyndham Boston Beacon Hill
5 Blossom Street, Boston, MA 02114
For further information or assistance, please visit www.wyndhambeaconhill.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including, without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH